We are what we exhale Every time that we exhale We release chemicals
Scientists can analyze our breath They collect all the chemicals …and tell you how healthy are your lungs!
Now imagine what we can do… lung information piece of exhaled air
The answer is… We are a company that develops medical devices to analyze breath and diagnose “tuberculosis” and “aspergillus” at same TIME!
Why tuberculosis and aspergillus? Chronic pulmonary aspergillosis is often confused with tuberculosis Over 3 million affected worldwide How many in the UK AIAH? Images should be uniform Complement the text Not impact on copy area
Market
Product: Voltron 1.0 Evaldas summarize here. IP property, How much we spent? And first funding was a grant
Product: Voltron 1.0 In 2014 we started to collect literature information about volatile biomarkers. First prototype of mask Validation with clinical trials at the National Center of Aspergillus in Southern Manchester, notified to the MHRA (Medicines and Healthcare products Regulatory Agency), fee £5,040 Conformity assessment for CE marking carried out by BSI Healthcare, fee £8,000 Licensing to Omega Diagnostic Ltd (Manufacture) Licensing to Avenzys Medical (Distributor)
Feasibility & Sustainability
Operations & Human Resources
Financials & Profitability
Roadmap